Retatrutide, a new dual activator of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) binding site , is demonstrating promising data in early human trials . Current examination https://getsocialsource.com/story6839145/retatrutide-emerging-investigations-and-possible-clinical-roles